Free Trial
NASDAQ:FDMT

4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

4D Molecular Therapeutics logo
$2.88 -0.40 (-12.20%)
Closing price 04:00 PM Eastern
Extended Trading
$2.98 +0.10 (+3.44%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)

Key Stats

Today's Range
$2.88
$3.12
50-Day Range
$2.88
$6.52
52-Week Range
$2.87
$29.27
Volume
555,304 shs
Average Volume
815,813 shs
Market Capitalization
$133.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.71
Consensus Rating
Moderate Buy

Company Overview

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Remove Ads

4D Molecular Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

FDMT MarketRank™: 

4D Molecular Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 610th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 6 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    4D Molecular Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about 4D Molecular Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.84) to ($3.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 4D Molecular Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 4D Molecular Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    4D Molecular Therapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about 4D Molecular Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.74% of the float of 4D Molecular Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    4D Molecular Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in 4D Molecular Therapeutics has recently decreased by 4.01%, indicating that investor sentiment is improving.
  • Dividend Yield

    4D Molecular Therapeutics does not currently pay a dividend.

  • Dividend Growth

    4D Molecular Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.74% of the float of 4D Molecular Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    4D Molecular Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in 4D Molecular Therapeutics has recently decreased by 4.01%, indicating that investor sentiment is improving.
  • Search Interest

    Only 2 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.30% of the stock of 4D Molecular Therapeutics is held by insiders.

  • Percentage Held by Institutions

    99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 4D Molecular Therapeutics' insider trading history.
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FDMT Stock News Headlines

4DMT to Participate in Upcoming Investor Conferences
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
4D Molecular Therapeutics (FDMT) Gets a Buy from Barclays
See More Headlines

FDMT Stock Analysis - Frequently Asked Questions

4D Molecular Therapeutics' stock was trading at $5.57 at the start of the year. Since then, FDMT stock has decreased by 48.3% and is now trading at $2.88.
View the best growth stocks for 2025 here
.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) released its quarterly earnings results on Friday, February, 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.10.

4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
2/28/2025
Today
4/03/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FDMT
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.71
High Stock Price Target
$40.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+790.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-100,840,000.00
Pretax Margin
-843,999.81%

Debt

Sales & Book Value

Annual Sales
$37,000.00
Price / Cash Flow
N/A
Book Value
$7.20 per share
Price / Book
0.42

Miscellaneous

Free Float
42,853,000
Market Cap
$138.91 million
Optionable
Optionable
Beta
2.83
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:FDMT) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners